Latest news with #Biopharmaceuticals
Yahoo
6 days ago
- Business
- Yahoo
Favorable Government Support Fuels Germany's Biotech Innovation and Commercialization: Market to Surpass USD 94 Billion by 2034 Led by QIAGEN, Thermo Fisher Scientific, Illumina and Roche
German Biotechnology Market Dublin, July 18, 2025 (GLOBE NEWSWIRE) -- The "Germany Biotechnology Market Report and Forecast 2025-2034" has been added to Germany biotechnology market was valued at USD 35.30 Billion in 2024, bolstered by robust public and private investment in biotech innovation, alongside significant R&D endeavors supported by established academic and research institutions. The market is expected to grow at a CAGR of 10.30% during 2025-2034, potentially reaching USD 94.09 Billion by 2034. Government initiatives and funding play a critical role in accelerating the development and commercialization of advanced biotechnological solutions, contributing to market expansion. This growth is also underpinned by strong infrastructure, substantial R&D capabilities, and a skilled workforce. The increasing adoption of precision medicine and biopharmaceuticals is anticipated to further drive market growth in the forecast period. Increasing Prevalence of Chronic Diseases The market's growth is heavily influenced by the rising incidence of chronic and degenerative diseases. According to WHO data from 2021, conditions such as ischemic heart disease, Alzheimer's disease, stroke, various cancers, COPD, and kidney disorders impose a significant health burden, intensifying demand for innovative diagnostics, targeted therapies, and precision medicine. This drives forward the biotechnology sector, bolstered by increased research and development investments from both public and private sectors. Germany Biotechnology Market Trends Key trends include rising investments and the advent of cutting-edge, sustainable technologies. Investment confidence continues to grow, evidenced by a 78% increase in funding for German biotech firms, reaching EUR 1.917 billion in 2024, according to BIO Deutschland and EY. This capital influx is set to enhance market growth and technological progress. Additionally, innovative, eco-friendly food technologies are driving demand. In March 2024, the launch of Kynda's zero-waste mycelium-based food product in Germany highlighted a move towards sustainable consumer solutions, anticipating an increase in the market's growth and the adoption of sustainable biotech products. Germany Biotechnology Market Segmentation The market analysis includes segments such as: Product Type: Instruments, Reagents, Software and Services, Others Technology: Nanobiotechnology, Tissue Engineering, DNA Sequencing, Cell-based Assays, Fermentation, PCR Technology, Chromatography, Others Application: Health, Food & Agriculture, Natural Resources & Environment, Industrial Processing, Bioinformatics, Others Germany Biotechnology Market Share: DNA Sequencing's Impact The biotechnology market in Germany is diversified across various technologies, with DNA sequencing anticipated to lead. Innovations like Merck's Aptegra platform, which integrates multiple assays into one, significantly reduce testing times and costs, driving DNA sequencing's important role in the market's future growth. Leading Players in the Germany Biotechnology Market The major market players include: QIAGEN N.V: Expanded its portfolio by acquiring Genoox, enhancing AI-driven genetic data interpretation for clinical decision-making. Thermo Fisher Scientific, Inc: Introduced sustainable centrifuges in Germany, boosting energy efficiency in bioprocessing. Illumina Inc: Partnered with to launch an extensive clinical multiomic dataset, propelling advancements in metabolic disease therapies. F. Hoffman-La Roche Ltd: Gained FDA clearance for a dual mRNA probe assay improving B-cell lymphoma diagnostics. Other key companies include Evotec SE, Bio-Rad Laboratories, Agilent Technologies, and BioNTech SE. Key Questions Answered What was the Germany biotechnology market value in 2024? What is the forecast for 2025-2034? What drives demand in the market? How has the market performed historically, and future expectations? What are the major trends and challenges? Which product, technology, and application segments are expected to dominate? Who are the key players? Key Attributes Report Attribute Details No. of Pages 250 Forecast Period 2025-2034 Estimated Market Value (USD) in 2025 $35.3 Billion Forecasted Market Value (USD) by 2034 $94.09 Billion Compound Annual Growth Rate 10.3% Regions Covered Germany Key Topics Covered 1 Preface 1.1 Objectives of the Study 1.2 Key Assumptions 1.3 Report Coverage - Key Segmentation and Scope 1.4 Research Methodology 2 Executive Summary 3 Biotechnology Market Overview 3.1 Europe Biotechnology Market 3.2 Germany Biotechnology Market 4 Vendor Positioning Analysis 4.1 Key Vendors 4.2 Prospective Leaders 4.3 Niche Leaders 4.4 Disruptors 5 Germany Biotechnology Market Landscape 5.1 Germany Biotechnology Market: Developers Landscape 5.2 Germany Biotechnology Market: Product Landscape 6 Germany Biotechnology Market Dynamics 6.1 Market Drivers and Constraints 6.2 SWOT Analysis 6.3 PESTEL Analysis 6.4 Porter's Five Forces Model 6.5 Key Demand Indicators 6.6 Key Price Indicators 6.7 Industry Events, Initiatives, and Trends 6.8 Value Chain Analysis 7 Germany Biotechnology Market Segmentation (2018-2034) 7.1 By Product Type 7.2 By Technology 7.3 By Application 8 Regulatory Framework 9 Patent Analysis 10 Funding and Investment Analysis 11 Strategic Initiatives 12 Supplier Landscape 13 Germany Biotechnology Market - Distribution Model (Additional Insight) 14 Key Opinion Leaders (KOL) Insights (Additional Insight) For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment German Biotechnology Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
30-06-2025
- Business
- Yahoo
Protein Expression Market to Reach $5 Billion by 2032, Growing at a CAGR of 7.6% from 2025, Says Meticulous Research®
Market Growth Driven by Rising Biopharmaceutical Demand, Recombinant Protein Development, and Government Life Science Research Funding REDDING, Calif., June 30, 2025 /PRNewswire/ -- According to a comprehensive market research report titled "Protein Expression Market by System (Mammalian [CHO, HEK 293], Non-mammalian [Bacterial, Insect, Yeast]), Offering (Kits & Reagents, Vectors, Competent Cells, Services), Application (Industrial, Therapeutic, Research), and End User—Global Forecast to 2032", the Protein Expression market is projected to reach $5.0 billion by 2032, growing at a robust CAGR of 7.6% during the forecast period from 2025. The significant growth of the protein expression market is driven by the rapidly expanding biopharmaceutical sector, increasing demand for recombinant proteins across therapeutic and research applications, and substantial government initiatives supporting life science research and development. The market's expansion is fueled by the growing adoption of biosimilars in oncology and autoimmune diseases, emerging opportunities in underpenetrated economies, and the critical need for advanced protein synthesis technologies across pharmaceutical research, biotechnology development, and industrial applications. The industry is experiencing transformational growth through advanced mammalian cell expression systems, innovative recombinant protein technologies, and specialized solutions for therapeutic protein production. Leading companies are investing heavily in contract research organization partnerships while expanding manufacturing capabilities to meet the surging demand for biopharmaceuticals and developing customized protein expression platforms for diverse research and industrial applications. For more comprehensive insights, download the FREE report sample: Revolutionary Market Transformation Through Advanced Protein Synthesis Technologies The protein expression market represents a critical evolution in biopharmaceutical development and biotechnology research. As the healthcare industry faces increasing demand for personalized medicine and novel therapeutic proteins, protein expression systems offer comprehensive platforms that address the growing complexity of recombinant protein production, biosimilar development, and advanced research applications across therapeutic and industrial sectors. Market leaders are investing substantially in mammalian cell expression technologies, advanced recombinant DNA systems, and sustainable protein production methods, establishing manufacturing capabilities that can deliver high-yield, high-quality protein synthesis solutions for pharmaceutical companies, biotechnology firms, and academic research institutions. This technological advancement is making sophisticated protein expression systems increasingly accessible to emerging biopharmaceutical companies while delivering enterprise-grade performance and comprehensive regulatory compliance capabilities. Dynamic Growth Across Key Market Segments Based on system type, the Mammalian Cell Expression System segment dominates the market in 2025, capturing the largest share due to their low risk of cross-contamination, elimination of post-translational modification requirements, and wider acceptance for therapeutic applications. Mammalian systems, particularly CHO (Chinese Hamster Ovary) and HEK 293 (Human Embryonic Kidney) cells, provide superior protein folding capabilities and native glycosylation patterns essential for therapeutic protein production, making them indispensable for biopharmaceutical manufacturing and clinical research applications. Based on products and services, the Reagents segment is expected to dominate the market in 2025, reflecting their frequent utilization across research, therapeutic development, and industrial protein production processes. The widespread adoption of specialized reagents for protein expression, purification, and analysis drives consistent demand across all end-user segments. Based on application, the Research segment is projected to register the highest CAGR during the forecast period, driven by expanding R&D expenditure, emergence of new disease targets, and increasing focus on pharma-academic collaborations for advanced protein research and drug discovery initiatives. Based on end-user, the Contract Research Organizations (CROs) segment is expected to exhibit the highest CAGR, reflecting the growing trend of pharmaceutical and biotechnology companies outsourcing protein expression services to specialized providers, supported by government initiatives expanding research activities and cost-optimization strategies in drug development. Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) - Strategic Market Opportunities and Innovation Drivers The market presents exceptional growth opportunities through biosimilar development expansion, emerging economy penetration, and advancement of specialized expression systems for complex therapeutic proteins. Companies are discovering new revenue streams through contract manufacturing services, customized expression platforms, and comprehensive protein production ecosystems while establishing advanced capabilities for large-scale biopharmaceutical manufacturing. Key market drivers include: Expanding Biopharmaceutical Market: Rapid growth in biologics development, biosimilar production, and personalized medicine creating unprecedented demand for scalable, high-quality protein expression systems across therapeutic applications Rising Recombinant Protein Demand: Increasing adoption of recombinant proteins in therapeutics, vaccines, and industrial applications due to advantages including reduced immune reaction risk, elimination of protein contaminants, and shorter production lead times Government Research Funding: Substantial public and private investment in life science research, biotechnology development, and healthcare innovation driving demand for advanced protein expression technologies in academic and research institutions Biosimilar Market Growth: Significant expansion of biosimilar therapeutics in oncology, autoimmune diseases, and rare conditions, supported by favorable regulatory frameworks and cost advantages compared to originator biologics Emerging Economy Opportunities: Rapid biopharmaceutical industry development in China, India, and other emerging markets creating substantial demand for protein expression systems and contract research services Contract Research Expansion: Growing trend of pharmaceutical companies outsourcing protein expression services to specialized CROs for cost optimization, risk mitigation, and access to advanced technologies Regional Market Leadership and Emerging Growth Asia-Pacific emerges as the fastest-growing region during the forecast period, driven by substantial investments in life science research across China and India, growing preference for recombinant technology advantages, and expanding biopharmaceutical manufacturing capabilities. The region benefits from increasing government initiatives supporting biosimilar development, rising pharmaceutical R&D expenditure, and growing demand for biologics across diverse therapeutic areas. Asia-Pacific's rapid growth is further propelled by the development of multinational clinical centers, accelerated approval processes for specialty medicines, and introduction of Marketing Authorization Holder (MAH) frameworks enabling efficient biosimilar commercialization. The region's emerging economies offer significant advantages including infrastructure development investments, competitive labor costs, improving adherence to global manufacturing standards, and increasing regulatory oversight supporting international market access. North America represents a substantial established market supported by mature biopharmaceutical industries, comprehensive regulatory frameworks, and concentration of leading pharmaceutical and biotechnology companies requiring advanced protein expression technologies. The region's robust research infrastructure creates significant opportunities for specialized protein expression solutions and contract research services. Europe maintains strong market presence driven by established biopharmaceutical industries, comprehensive regulatory standards, and emphasis on innovative therapeutic development. The region's diverse biotechnology sectors, including biosimilar development and specialized therapeutics, create substantial demand for advanced protein expression technologies. Request a customized research analysis tailored to your specific requirements: Dynamic Competitive Landscape Driving Innovation The global protein expression market features a sophisticated competitive ecosystem comprising established biotechnology leaders, specialized protein expression technology providers, and innovative contract research organizations. This diverse landscape fosters rapid technological advancement and comprehensive solution development across therapeutic, research, and industrial applications. Industry leaders are implementing integrated protein expression platforms that combine advanced mammalian cell systems, specialized reagents, and comprehensive service offerings. Companies are pursuing strategic partnerships with pharmaceutical companies and academic institutions while addressing evolving regulatory requirements across diverse therapeutic applications and international markets. Immediate Delivery Available | Buy this Research Report (Insights, Charts, Tables, Figures and More) - Market Leaders Shaping Industry Future Key players driving the global protein expression market include Thermo Fisher Scientific Inc. (U.S.), Promega Corporation (U.S.), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (U.S.), Takara Holdings Inc. (Japan), GenScript Biotech Corporation (U.S.), Qiagen N.V. (Germany), Agilent Technologies, Inc. (U.S.), Danaher Corporation (U.S.), and BECTON, DICKINSON AND COMPANY (U.S.). Latest Industry Developments Recent market developments reflecting industry innovation include: Biosimilar Manufacturing Expansion: Major biopharmaceutical companies expanding manufacturing facilities to meet growing biosimilar demand, including strategic partnerships such as Biocon Ltd. and Mylan N.V.'s biosimilar business combination creating larger-scale production capabilities Contract Research Organization Growth: Rapid expansion of CRO services in emerging economies, driven by pharmaceutical companies' increasing focus on outsourcing protein expression services for cost optimization and risk mitigation Advanced Expression System Development: Investment in next-generation mammalian cell expression technologies offering enhanced protein yields, improved quality control, and streamlined production processes for complex therapeutic proteins Emerging Market Penetration: Strategic expansion into underpenetrated markets across Asia-Pacific and Latin America, capitalizing on growing biopharmaceutical demand, increasing aging populations, and rising disposable income supporting healthcare access Academia-Pharma Collaboration: Increasing partnerships between pharmaceutical companies and academic research institutions for advanced protein research, drug discovery, and therapeutic development leveraging specialized expression technologies Related Reports: DNA Sequencing Market Forecast: Next-Generation Sequencing Technologies Analysis Through 2032 Protein Assays Market Analysis: Technology Analysis Through 2032 Digital Therapeutics Market: Software-Based Therapeutic Applications Analysis Through 2031 About Meticulous Research We are a trusted research partner for leading businesses worldwide, empowering Fortune 500 organizations and emerging enterprises with market intelligence designed to drive revenue transformation and strategic growth. Our insights reveal future growth opportunities, equipping clients with a competitive edge through a versatile suite of research solutions—including syndicated reports, custom research, and direct analyst engagement. To find out more, visit or follow us on LinkedIn Contact:Mr. Khushal BombeMeticulous Market Research Pvt. Ltd.1267 Willis St, Ste 200 Redding,California, 96001, +1-646-781-8004Europe: +44-203-868-8738APAC: +91 744-7780008Email- sales@ Our Website: with us on LinkedIn- Source: Logo: View original content: SOURCE Meticulous Market Research Pvt. Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-06-2025
- Business
- Yahoo
MannKind (MNKD) Presents Pediatric Insulin Trial Data
MannKind Corporation (NASDAQ:MNKD) is one of the 11 Best US Stocks to Invest in Under $5. MannKind Corporation (NASDAQ:MNKD) reported that it will present its inhaled insulin product at the American Diabetes Association's 85th Scientific Sessions, which is taking place from June 20 to June 23 in Chicago. During a 'Future Ready' symposium, Dr. Michael J. Haller, Professor and Chief of Pediatric Endocrinology at the University of Florida, will share results from the randomized period of the INHALE-1 clinical trial. Dr. Haller also serves as the Chair for MannKind Corporation's (NASDAQ:MNKD) Phase 3 INHALE-1 study of Afrezza, an inhaled insulin powder, in children and adolescents between 4 and 17 years old. A close-up of a doctor's hand pressing on an inhaler, conveying the effect of the company's therapeutic products. MannKind Corporation (NASDAQ:MNKD) aims to release the topline results from the full pediatric study with safety extension in the second quarter of 2025. The company also expects to submit a Supplemental Biologics License Application in mid-2025 for a possible pediatric indication for Afrezza. MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company focused on developing and commercializing innovative inhaled therapeutic products and devices for those living with endocrine and orphan lung diseases. While we acknowledge the potential of MNKD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Stocks That Will Bounce Back According To Analysts and 11 Best Stocks Under $15 to Buy According to Hedge Funds. Disclosure: None.
Asharq Al-Awsat
22-05-2025
- Business
- Asharq Al-Awsat
South Korea to Prepare Support for Food Exporters to Weather US Tariffs
South Korea will prepare support measures for agricultural and food exporters, while closely monitoring the impact of US tariffs on the sector, the finance ministry said on Thursday. The United States is the biggest export market for the sector, with more growth potential expected from a boom in demand for South Korean foods, the ministry said in a statement after a meeting to review government responses to US tariffs. South Korean officials travelled to Washington, D.C. this week for a second round of working-level technical discussions, with officials from the agriculture ministry included in the negotiation team. On Wednesday, South Korea pledged more support measures for key export industries such as biopharmaceuticals and autos, as US President Donald Trump's sweeping tariffs weigh on the trade-reliant economy.
Globe and Mail
16-05-2025
- Business
- Globe and Mail
Protein Expression Market to Hit USD 4.82 Billion by 2029 with 7.1% CAGR
Browse 632 market data Tables and 71 Figures spread through 470 Pages and in-depth TOC on "Protein Expression Market by Product (Reagents, Vectors, Competent Cells, Instruments, Software), Services, System Type (Mammalian (CHO, HEK293), Insect, Yeast), Workflow, Application (Therapeutic, Research, Industrial) - Global Forecast to 2029 The global protein expression market growth forecasted to transform from USD 3.41 billion in 2024 to USD 4.82 billion by 2029, driven by a CAGR of 7.1%. Factors such as the rise in R&D within the pharmaceutical and biopharmaceutical industries owing to the increasing demand for biologics and the growing use of artificial intelligence and machine learning to enhance protein expression workflow, drive the growth of the protein expression market. Other factors such as the growing clinical activities outsourcing trend and an increasing shift toward personalized medicines support the growth of the protein expression market. Furthermore, advancements in synthetic protein production technologies and the growing use of recombinant proteins provide growth opportunities for companies operating in the protein expression market. However, the high cost of protein expression offerings and the dominance of small molecules in drug development are expected to restrain the growth of this market to a certain extent. Browse in-depth TOC on 'Protein Expression Market' 632 - Tables 71 - Figures 470 - Pages Based on system type, the protein expression market is segmented into mammalian cell expression systems, prokaryotic expression systems, cell-free expression systems, yeast expression systems, insect cell expression systems, and algal-based expression systems. In 2023, the mammalian cell expression systems segment held the largest share of the global protein expression market, owing to the preference given to these systems to produce complex proteins such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and vaccines. Among these systems, Chinese hamster ovary (CHO) cells are the most used due to their rapid growth and high protein expression capabilities. The protein expression market has been segmented based on application into three segments, including industrial application, research application, and therapeutic applications. In 2023, the therapeutic application segment had the highest market share across the protein expression market. This segment of the application is growing because of the increasing cases of chronic diseases like diabetes, cardiovascular diseases, and neurological disorders that are supporting the demand for protein-based therapies such as mAb and vaccines. Moreover, the segmental growth is further supported by the increased focus on the production of personalized medicine through grants and funding support. Based on offerings, the protein expression market is segmented into products and services. The products are segmented further into expression vectors, competent cells, reagents & kits, instruments, and software. In 2023, the protein expression market was dominated by the products segment. This large share can be attributed to the growing research alongside the rising approvals and commercialization of biologics, for example, antibodies. The reagents & kits sub-segment held the majority share under the products segment since the demand for reagents & kits persists in the sphere of research. This is because they need to be refilled periodically throughout the process of protein expression. Moreover, companies are launching innovative products for advanced protein expression workflows further supporting the growth prospects for the products segment. Based on end users of protein expression products, the protein expression market is segmented into contract research organizations & contract development and manufacturing organizations (CROS and CDMOs), pharmaceutical and biotechnology companies, and academic & research institutes, and other end users. In 2023, the pharmaceutical and biotechnology companies held the largest share of the global protein expression product market, and this growth trend is expected to continue during the forecast period. The large share of this end-user segment is supported by the increase in the demand for therapeutic proteins and the rising approvals for recombinant therapeutic proteins for disease treatment. The protein expression market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa based on region. In 2023, North America held the largest share of the protein expression market, followed by Europe. The presence of major suppliers and key end users for the protein expression offerings in the region supports the large share of the North American protein expression market. Other drivers include growth in the biotechnology and pharmaceuticals industries, the growing prevalence of chronic disorders, and investments in the research and development of protein-based therapeutics research that contribute to furthering this large share of this market. North America is expected to dominate this space during the forecast period. The protein expression market is highly consolidated. The top players in this market hold a significant share of the total market. Prominent market players include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Sartorius AG (Germany), Agilent Technologies, Inc. (US), Bio-Rad Laboratories, Inc. (US), Takara Bio Inc. (Japan), GenScript (US), and Eurofins Scientific (Luxembourg). These companies have adopted various strategies such as the development of advanced products, partnerships, contracts, expansions, and acquisitions to strengthen their position in the protein expression market. The organic and inorganic strategies have helped the market players expand globally by providing advanced authentication and brand protection solutions. However, the high market consolidation acts as a barrier for new entrants in the market. Thermo Fisher Scientific Inc. (US) is the largest player in the protein expression market offering a wide range of protein expression products and services, including expression systems and kits, expression vectors, competent cells, and instruments such as electroporators and MS systems. The company has a significant global footprint due to its robust sales and distribution network. Additionally, multiple production sites at various geographic locations give the company an edge over other players in the protein expression market. With the reduced demand for COVID-19 products, the company has shifted its focus toward strengthening its core business. The company acquired PPD in 2021 to enhance its clinical research capabilities, allowing it to maintain its leadership in vaccine and therapy development supporting its leadership in the protein expression market. Moreover, in June 2021, Thermo partnered with Advanced Electrophoresis Solutions Ltd. (AES) (Canada) to enhance therapeutic protein development by utilizing protein separation techniques. The company aims to expand its market presence by investing in R&D, which enhances its expertise in protein expression solutions and services, allowing it to offer innovative products and services to the market. Merck KGaA (Germany) is a key player in the protein expression market. The company offers a wide range of protein expression solutions and services, such as assays, reagents, devices, software, protein sample preparation services, and detection & quantification kits, through its science & lab solutions subsegment under its life science business unit. With a strong geographic presence in over 120 countries, Merck KGaA focuses on expanding its customer base, particularly in the fast-growing Asia Pacific region, where it established life science centers in China, India, South Korea, and Singapore from 2021 to 2023. To maintain its market leadership, the company has made significant investments in research and development. For instance, in 2023, the company allocated USD 2.6 billion toward R&D to enhance its product offerings. Additionally, between 2022 and 2024, it expanded its manufacturing and research facilities in Germany, China, France, and Ireland. By prioritizing digitalization, automation, and process improvements, along with these strategic investments, the company seeks to further strengthen its global market presence and ensure sustainable growth. Danaher Corporation (US) is a key player in the protein expression market owing to its strong product portfolio including reagents, kits, and instruments used throughout the protein expression process. The company leverages its strong geographic presence and advanced technological capabilities to maintain its position in the protein expression market. The company focuses on acquisitions, collaborations, and expansions, such as the 2022 acquisition of CEVEC Pharmaceuticals to support and improve its protein expression portfolio. In the same year, Danaher's subsidiary, Cytiva, collaborated with Nucleus Biologics to improve custom cell media development for cell and gene therapies. Moreover, in 2022, the company established its chromatography resins manufacturing facility in the US, supporting protein purification and analysis. In 2023, the company's Life Sciences segment saw a 1.5% sales increase, driven by a 4.0% price rise, higher core sales in life science research, and contributions from acquisitions. These strategic moves have helped Danaher become a dominant player in the protein expression market. Agilent Technologies, Inc. (US) is a life science company offering various instruments, software, services, and consumables to support laboratory operations. Their extensive portfolio includes protein expression products such as competent cells, expression vectors, protein purification kits, and transfection tools. Agilent Technologies, Inc. has its primary R&D and manufacturing sites in the US, Australia, China, Denmark, Germany, India, Italy, Malaysia, Poland, Singapore, and the UK. The company utilizes direct sales channels as well as distributors, resellers, and electronic commerce to distribute its offerings. The company increased its R&D investments in the Life Sciences and Applied Markets segment by 1% from the previous year (2022), totalling USD 297 million in 2023. This funding helps develop new and innovative products and solutions to meet the changing needs of clients. For more information, Inquire Now!
